Multi-functional gene ZNF281 identified as a molecular biomarker in soft tissue regeneration and pan-cancer progression

Regeneration and tumorigenesis are indicated as related processes, while regeneration leads to life and the outcome of tumorigenesis is death. Here, we show the upregulation of (zinc finger 281) in our adipose regeneration model through RNA-seq analysis. Then, we validated the upregulation of zfp281...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in genetics Vol. 13; p. 1082654
Main Authors Hou, Xueying, Luan, Jie, Fu, Su
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 05.01.2023
Subjects
biomarker
Genetics
pan-cancer
regeneration
tumorigenesis
ZNF281
pan-cancer
tumorigenesis
biomarker
regeneration
ZNF281
Online AccessGet full text

Cover

More Information
Summary:Regeneration and tumorigenesis are indicated as related processes, while regeneration leads to life and the outcome of tumorigenesis is death. Here, we show the upregulation of (zinc finger 281) in our adipose regeneration model through RNA-seq analysis. Then, we validated the upregulation of zfp281 in adipose regeneration immunofluorescence. Following that, we found that (the human homolog of ) was upregulated in most types of cancer and related to worse prognosis in 10 tumors. We further investigated the role of in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), pancreatic adenocarcinoma (PAAD), and stomach adenocarcinoma (STAD) and confirmed the high accuracy in the clinical diagnostic feature. Beyond that, based on these three types of cancers, we analyzed the -related tumor immune infiltration and DNA methylation sites and finally built risk prediction models for future disease diagnosis. Taken together, our findings provide new insights into the dual role of , and we found that it was a potential biomarker for regeneration and tumor prognosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Xiaokang Zhang, Beijing Tiantan Hospital, Capital Medical University, China
These authors have contributed equally to this work and share last authorship
This article was submitted to Cancer Genetics and Oncogenomics, a section of the journal Frontiers in Genetics
Edited by: Jiao Hu, Xiangya Hospital, Central South University, China
Reviewed by: Jian Kang, Northeastern University, China
Zhixiang Yu, Fourth Military Medical University, China
ISSN:1664-8021
1664-8021
DOI:10.3389/fgene.2022.1082654